10-Q Filing

ARROWHEAD PHARMACEUTICALS, INC. CIK: 879407 Q3 2015

Filing Information

Form Type	10-Q
Accession Number	`0001564590-15-006064`
Period End Date	20150630
Filing Date	20150804
Fiscal Year	2015
Fiscal Period	Q3
XBRL Instance	arwr-20150630.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 85 Income Statement 81 Cash Flow Statement 73 Stockholders Equity 26

Balance Sheet 85 line items

Line Item	Tag	Value	Unit	Period
Preferred stock, par value	`PreferredStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Preferred stock, par value	`PreferredStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Preferred stock, shares authorized	`PreferredStockSharesAuthorized`	5.00M	shares	Point-in-time
Preferred stock, shares authorized	`PreferredStockSharesAuthorized`	5.00M	shares	Point-in-time
Preferred stock, shares issued	`PreferredStockSharesIssued`	15,652.00	shares	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$87.25M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$138.35M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$19.11M	USD	Point-in-time
Preferred stock, shares issued	`PreferredStockSharesIssued`	18,300.00	shares	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$132.51M	USD	Point-in-time
Preferred stock, shares outstanding	`PreferredStockSharesOutstanding`	18,300.00	shares	Point-in-time
Prepaid expenses	`PrepaidExpenseCurrent`	$588.63K	USD	Point-in-time
Preferred stock, shares outstanding	`PreferredStockSharesOutstanding`	15,652.00	shares	Point-in-time
Prepaid expenses	`PrepaidExpenseCurrent`	$3.50M	USD	Point-in-time
Common stock, par value	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Common stock, par value	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Other current assets	`OtherAssetsCurrent`	$654.92K	USD	Point-in-time
Other current assets	`OtherAssetsCurrent`	$48.50K	USD	Point-in-time
Short term investments	`HeldToMaturitySecuritiesCurrent`	$23.28M	USD	Point-in-time
Short term investments	`HeldToMaturitySecuritiesCurrent`	$21.65M	USD	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	145.00M	shares	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	145.00M	shares	Point-in-time
Common stock, shares issued	`CommonStockSharesIssued`	54.66M	shares	Point-in-time
TOTAL CURRENT ASSETS	`AssetsCurrent`	$154.80M	USD	Point-in-time
TOTAL CURRENT ASSETS	`AssetsCurrent`	$114.69M	USD	Point-in-time
Common stock, shares issued	`CommonStockSharesIssued`	59.50M	shares	Point-in-time
Common stock, shares outstanding	`CommonStockSharesOutstanding`	59.50M	shares	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$3.87M	USD	Point-in-time
Common stock, shares outstanding	`CommonStockSharesOutstanding`	54.66M	shares	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$4.11M	USD	Point-in-time
Intangible assets, net	`IntangibleAssetsNetExcludingGoodwill`	$3.24M	USD	Point-in-time
Intangible assets, net	`IntangibleAssetsNetExcludingGoodwill`	$1.01M	USD	Point-in-time
Intangible assets, net	`IntangibleAssetsNetExcludingGoodwill`	$25.26M	USD	Point-in-time
Investments	`HeldToMaturitySecuritiesNoncurrent`	$23.09M	USD	Point-in-time
Investments	`HeldToMaturitySecuritiesNoncurrent`	$1.09M	USD	Point-in-time
Other assets	`OtherAssetsMiscellaneousNoncurrent`	$41.41K	USD	Point-in-time
Other assets	`OtherAssetsMiscellaneousNoncurrent`	$45.79K	USD	Point-in-time
TOTAL ASSETS	`Assets`	$145.19M	USD	Point-in-time
TOTAL ASSETS	`Assets`	$182.82M	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$4.86M	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$2.58M	USD	Point-in-time
Accrued expenses	`AccruedLiabilitiesCurrent`	$1.40M	USD	Point-in-time
Accrued expenses	`AccruedLiabilitiesCurrent`	$1.73M	USD	Point-in-time
Accrued payroll and benefits	`EmployeeRelatedLiabilitiesCurrent`	$3.27M	USD	Point-in-time
Accrued payroll and benefits	`EmployeeRelatedLiabilitiesCurrent`	$884.37K	USD	Point-in-time
Deferred revenue	`DeferredRevenueCurrent`	$103.12K	USD	Point-in-time
Deferred revenue	`DeferredRevenueCurrent`	$71.88K	USD	Point-in-time
Derivative liabilities	`DerivativeLiabilitiesCurrent`	$1.72M	USD	Point-in-time
Derivative liabilities	`DerivativeLiabilitiesCurrent`	$4.17M	USD	Point-in-time
Capital lease obligation	`CapitalLeaseObligationsCurrent`	$213.99K	USD	Point-in-time
Capital lease obligation	`CapitalLeaseObligationsCurrent`	$216.65K	USD	Point-in-time
Notes payable	`NotesPayableCurrent`	$50.00K	USD	Point-in-time
Other current liabilities	`OtherLiabilitiesCurrent`	$58.49K	USD	Point-in-time
Other current liabilities	`OtherLiabilitiesCurrent`	$46.41K	USD	Point-in-time
TOTAL CURRENT LIABILITIES	`LiabilitiesCurrent`	$9.53M	USD	Point-in-time
TOTAL CURRENT LIABILITIES	`LiabilitiesCurrent`	$11.85M	USD	Point-in-time
Capital lease obligation, net of current portion	`CapitalLeaseObligationsNoncurrent`	$758.34K	USD	Point-in-time
Capital lease obligation, net of current portion	`CapitalLeaseObligationsNoncurrent`	$595.52K	USD	Point-in-time
Contingent consideration obligations	`BusinessCombinationContingentConsiderationLiability`	$3.97M	USD	Point-in-time
Contingent consideration obligations	`BusinessCombinationContingentConsiderationLiability`	$1.60M	USD	Point-in-time
Contingent consideration obligations	`BusinessCombinationContingentConsiderationLiability`	$3.97M	USD	Point-in-time
Other non-current liabilities	`OtherLiabilitiesNoncurrent`	$255.21K	USD	Point-in-time
Other non-current liabilities	`OtherLiabilitiesNoncurrent`	$347.00K	USD	Point-in-time
TOTAL LONG-TERM LIABILITIES	`LiabilitiesNoncurrent`	$4.91M	USD	Point-in-time
TOTAL LONG-TERM LIABILITIES	`LiabilitiesNoncurrent`	$4.98M	USD	Point-in-time
Commitments and contingencies	`CommitmentsAndContingencies`	-	USD	Point-in-time
Commitments and contingencies	`CommitmentsAndContingencies`	-	USD	Point-in-time
Preferred stock, $0.001 par value; 5,000,000 shares authorized; 15,652 and 18,300 shares issued and outstanding as of June 30, 2015 and September 30, 2014, respectively	`PreferredStockValue`	$16.00	USD	Point-in-time
Preferred stock, $0.001 par value; 5,000,000 shares authorized; 15,652 and 18,300 shares issued and outstanding as of June 30, 2015 and September 30, 2014, respectively	`PreferredStockValue`	$18.00	USD	Point-in-time
Common stock, $0.001 par value; 145,000,000 shares authorized; 59,498,362 and 54,656,936 shares issued and outstanding as of June 30, 2015 and September 30, 2014, respectively	`CommonStockValue`	$147.03K	USD	Point-in-time
Common stock, $0.001 par value; 145,000,000 shares authorized; 59,498,362 and 54,656,936 shares issued and outstanding as of June 30, 2015 and September 30, 2014, respectively	`CommonStockValue`	$151.87K	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$391.16M	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$423.18M	USD	Point-in-time
Accumulated other comprehensive income (loss)	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$-65.95K	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-224.77M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-291.97M	USD	Point-in-time
Total Arrowhead Research Corporation stockholders' equity	`StockholdersEquity`	$131.30M	USD	Point-in-time
Total Arrowhead Research Corporation stockholders' equity	`StockholdersEquity`	$166.54M	USD	Point-in-time
Noncontrolling interest	`MinorityInterest`	$-555.19K	USD	Point-in-time
Noncontrolling interest	`MinorityInterest`	$-555.19K	USD	Point-in-time
TOTAL STOCKHOLDERS EQUITY	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$130.74M	USD	Point-in-time
TOTAL STOCKHOLDERS EQUITY	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$165.99M	USD	Point-in-time
TOTAL STOCKHOLDERS EQUITY	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$25.73M	USD	Point-in-time
TOTAL LIABILITIES AND STOCKHOLDERS EQUITY	`LiabilitiesAndStockholdersEquity`	$182.82M	USD	Point-in-time
TOTAL LIABILITIES AND STOCKHOLDERS EQUITY	`LiabilitiesAndStockholdersEquity`	$145.19M	USD	Point-in-time

Income Statement 81 line items

Line Item	Tag	Value	Unit	Period
REVENUE	`Revenues`	$131.25K	USD	3 Qtrs
REVENUE	`Revenues`	$123.75K	USD	1 Quarter
REVENUE	`Revenues`	$43.75K	USD	1 Quarter
REVENUE	`Revenues`	$338.25K	USD	3 Qtrs
Research and development	`ResearchAndDevelopmentExpense`	$36.88M	USD	3 Qtrs
Research and development	`ResearchAndDevelopmentExpense`	$14.72M	USD	3 Qtrs
Research and development	`ResearchAndDevelopmentExpense`	$7.49M	USD	1 Quarter
Research and development	`ResearchAndDevelopmentExpense`	$6.39M	USD	1 Quarter
Acquired in-process research and development	`AcquiredInProcessResearchAndDevelopment`	$10.14M	USD	3 Qtrs
Salaries and payroll-related costs	`LaborAndRelatedExpense`	$2.45M	USD	1 Quarter
Salaries and payroll-related costs	`LaborAndRelatedExpense`	$7.63M	USD	3 Qtrs
Salaries and payroll-related costs	`LaborAndRelatedExpense`	$3.57M	USD	1 Quarter
Salaries and payroll-related costs	`LaborAndRelatedExpense`	$10.26M	USD	3 Qtrs
General and administrative expenses	`GeneralAndAdministrativeExpense`	$1.58M	USD	1 Quarter
General and administrative expenses	`GeneralAndAdministrativeExpense`	$5.61M	USD	3 Qtrs
General and administrative expenses	`GeneralAndAdministrativeExpense`	$3.87M	USD	3 Qtrs
General and administrative expenses	`GeneralAndAdministrativeExpense`	$1.83M	USD	1 Quarter
Stock-based compensation	`ShareBasedCompensation`	$2.04M	USD	1 Quarter
Stock-based compensation	`ShareBasedCompensation`	$3.76M	USD	3 Qtrs
Stock-based compensation	`ShareBasedCompensation`	$2.49M	USD	1 Quarter
Stock-based compensation	`ShareBasedCompensation`	$6.71M	USD	3 Qtrs
Depreciation and amortization	`DepreciationAndAmortization`	$276.05K	USD	1 Quarter
Depreciation and amortization	`DepreciationAndAmortization`	$1.08M	USD	3 Qtrs
Depreciation and amortization	`DepreciationAndAmortization`	$741.06K	USD	1 Quarter
Depreciation and amortization	`DepreciationAndAmortization`	$1.48M	USD	3 Qtrs
TOTAL OPERATING EXPENSES	`OperatingExpenses`	$16.12M	USD	1 Quarter
TOTAL OPERATING EXPENSES	`OperatingExpenses`	$12.74M	USD	1 Quarter
TOTAL OPERATING EXPENSES	`OperatingExpenses`	$31.05M	USD	3 Qtrs
TOTAL OPERATING EXPENSES	`OperatingExpenses`	$71.08M	USD	3 Qtrs
OPERATING LOSS	`OperatingIncomeLoss`	$-30.92M	USD	3 Qtrs
OPERATING LOSS	`OperatingIncomeLoss`	$-15.99M	USD	1 Quarter
OPERATING LOSS	`OperatingIncomeLoss`	$-70.74M	USD	3 Qtrs
OPERATING LOSS	`OperatingIncomeLoss`	$-12.70M	USD	1 Quarter
Equity in income (loss) of unconsolidated affiliates	`IncomeLossFromEquityMethodInvestments`	$-69.35K	USD	3 Qtrs
Equity in income (loss) of unconsolidated affiliates	`IncomeLossFromEquityMethodInvestments`	$78.70K	USD	1 Quarter
Gain (loss) on sale of fixed assets, net	`GainLossOnSaleOfPropertyPlantEquipment`	$19.20K	USD	3 Qtrs
Gain (loss) on sale of fixed assets, net	`GainLossOnSaleOfPropertyPlantEquipment`	$-58.88K	USD	3 Qtrs
Interest income (expense), net	`InterestIncomeExpenseNonoperatingNet`	$162.37K	USD	1 Quarter
Interest income (expense), net	`InterestIncomeExpenseNonoperatingNet`	$386.39K	USD	3 Qtrs
Interest income (expense), net	`InterestIncomeExpenseNonoperatingNet`	$226.42K	USD	1 Quarter
Interest income (expense), net	`InterestIncomeExpenseNonoperatingNet`	$597.90K	USD	3 Qtrs
Change in value of derivatives	`UnrealizedGainLossOnDerivatives`	$-104.71K	USD	1 Quarter
Change in value of derivatives	`UnrealizedGainLossOnDerivatives`	$-5.71M	USD	3 Qtrs
Change in value of derivatives	`UnrealizedGainLossOnDerivatives`	$2.45M	USD	3 Qtrs
Change in value of derivatives	`UnrealizedGainLossOnDerivatives`	$758.47K	USD	1 Quarter
Other income (expense)	`OtherNonoperatingIncomeExpense`	$482.90K	USD	3 Qtrs
Other income (expense)	`OtherNonoperatingIncomeExpense`	$81.27K	USD	3 Qtrs
Other income (expense)	`OtherNonoperatingIncomeExpense`	$10.05K	USD	1 Quarter
TOTAL OTHER INCOME (EXPENSE)	`NonoperatingIncomeExpense`	$3.55M	USD	3 Qtrs
TOTAL OTHER INCOME (EXPENSE)	`NonoperatingIncomeExpense`	$1.07M	USD	1 Quarter
TOTAL OTHER INCOME (EXPENSE)	`NonoperatingIncomeExpense`	$-5.37M	USD	3 Qtrs
TOTAL OTHER INCOME (EXPENSE)	`NonoperatingIncomeExpense`	$57.65K	USD	1 Quarter
LOSS BEFORE INCOME TAXES	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$-15.94M	USD	1 Quarter
LOSS BEFORE INCOME TAXES	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$-67.20M	USD	3 Qtrs
LOSS BEFORE INCOME TAXES	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$-36.29M	USD	3 Qtrs
LOSS BEFORE INCOME TAXES	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$-11.63M	USD	1 Quarter
NET LOSS	`ProfitLoss`	$-36.29M	USD	3 Qtrs
NET LOSS	`ProfitLoss`	$-11.63M	USD	1 Quarter
NET LOSS	`ProfitLoss`	$-67.20M	USD	3 Qtrs
NET LOSS	`ProfitLoss`	$-58.73M	USD	Annual
NET LOSS	`ProfitLoss`	$-15.94M	USD	1 Quarter
Net loss attributable to noncontrolling interests	`NetIncomeLossAttributableToNoncontrollingInterest`	$-95.13K	USD	3 Qtrs
Net loss attributable to noncontrolling interests	`NetIncomeLossAttributableToNoncontrollingInterest`	$2.47K	USD	1 Quarter
NET LOSS ATTRIBUTABLE TO ARROWHEAD	`NetIncomeLoss`	$-36.20M	USD	3 Qtrs
NET LOSS ATTRIBUTABLE TO ARROWHEAD	`NetIncomeLoss`	$-11.63M	USD	1 Quarter
NET LOSS ATTRIBUTABLE TO ARROWHEAD	`NetIncomeLoss`	$-15.94M	USD	1 Quarter
NET LOSS ATTRIBUTABLE TO ARROWHEAD	`NetIncomeLoss`	$-67.20M	USD	3 Qtrs
NET LOSS PER SHARE ATTRIBUTABLE TO ARROWHEAD SHAREHOLDERS - BASIC AND DILUTED:	`EarningsPerShareBasicAndDiluted`	$-0.27	USD	1 Quarter
NET LOSS PER SHARE ATTRIBUTABLE TO ARROWHEAD SHAREHOLDERS - BASIC AND DILUTED:	`EarningsPerShareBasicAndDiluted`	$-0.81	USD	3 Qtrs
NET LOSS PER SHARE ATTRIBUTABLE TO ARROWHEAD SHAREHOLDERS - BASIC AND DILUTED:	`EarningsPerShareBasicAndDiluted`	$-1.19	USD	3 Qtrs
NET LOSS PER SHARE ATTRIBUTABLE TO ARROWHEAD SHAREHOLDERS - BASIC AND DILUTED:	`EarningsPerShareBasicAndDiluted`	$-0.22	USD	1 Quarter
Weighted average shares outstanding - basic and diluted	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	56.63M	shares	3 Qtrs
Weighted average shares outstanding - basic and diluted	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	44.57M	shares	3 Qtrs
Weighted average shares outstanding - basic and diluted	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	51.93M	shares	1 Quarter
Weighted average shares outstanding - basic and diluted	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	59.49M	shares	1 Quarter
Foreign Currency Translation Adjustments	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$-65.95K	USD	3 Qtrs
Foreign Currency Translation Adjustments	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$-1.98K	USD	1 Quarter
COMPREHENSIVE LOSS ATTRIBUTABLE TO ARROWHEAD	`ComprehensiveIncomeNetOfTax`	$-11.63M	USD	1 Quarter
COMPREHENSIVE LOSS ATTRIBUTABLE TO ARROWHEAD	`ComprehensiveIncomeNetOfTax`	$-36.20M	USD	3 Qtrs
COMPREHENSIVE LOSS ATTRIBUTABLE TO ARROWHEAD	`ComprehensiveIncomeNetOfTax`	$-67.26M	USD	3 Qtrs
COMPREHENSIVE LOSS ATTRIBUTABLE TO ARROWHEAD	`ComprehensiveIncomeNetOfTax`	$-15.94M	USD	1 Quarter

Cash Flow Statement 73 line items

Line Item	Tag	Value	Unit	Period
Net loss	`ProfitLoss`	$-36.29M	USD	3 Qtrs
Net loss	`ProfitLoss`	$-11.63M	USD	1 Quarter
Net loss	`ProfitLoss`	$-67.20M	USD	3 Qtrs
Net loss	`ProfitLoss`	$-58.73M	USD	Annual
Net loss	`ProfitLoss`	$-15.94M	USD	1 Quarter
Net loss attributable to noncontrolling interests	`NetIncomeLossAttributableToNoncontrollingInterest`	$-95.13K	USD	3 Qtrs
Net loss attributable to noncontrolling interests	`NetIncomeLossAttributableToNoncontrollingInterest`	$2.47K	USD	1 Quarter
NET LOSS ATTRIBUTABLE TO ARROWHEAD	`NetIncomeLoss`	$-36.20M	USD	3 Qtrs
NET LOSS ATTRIBUTABLE TO ARROWHEAD	`NetIncomeLoss`	$-11.63M	USD	1 Quarter
NET LOSS ATTRIBUTABLE TO ARROWHEAD	`NetIncomeLoss`	$-15.94M	USD	1 Quarter
NET LOSS ATTRIBUTABLE TO ARROWHEAD	`NetIncomeLoss`	$-67.20M	USD	3 Qtrs
(Gain) loss on disposal of fixed assets	`GainLossOnSaleOfPropertyPlantEquipment`	$19.20K	USD	3 Qtrs
(Gain) loss on disposal of fixed assets	`GainLossOnSaleOfPropertyPlantEquipment`	$-58.88K	USD	3 Qtrs
Change in value of derivatives	`UnrealizedGainLossOnDerivatives`	$-104.71K	USD	1 Quarter
Change in value of derivatives	`UnrealizedGainLossOnDerivatives`	$-5.71M	USD	3 Qtrs
Change in value of derivatives	`UnrealizedGainLossOnDerivatives`	$2.45M	USD	3 Qtrs
Change in value of derivatives	`UnrealizedGainLossOnDerivatives`	$758.47K	USD	1 Quarter
Acquired in-process research and development	`AcquiredInProcessResearchAndDevelopment`	$10.14M	USD	3 Qtrs
Stock-based compensation	`ShareBasedCompensation`	$2.04M	USD	1 Quarter
Stock-based compensation	`ShareBasedCompensation`	$3.76M	USD	3 Qtrs
Stock-based compensation	`ShareBasedCompensation`	$2.49M	USD	1 Quarter
Stock-based compensation	`ShareBasedCompensation`	$6.71M	USD	3 Qtrs
Depreciation and amortization	`DepreciationAndAmortization`	$276.05K	USD	1 Quarter
Depreciation and amortization	`DepreciationAndAmortization`	$1.08M	USD	3 Qtrs
Depreciation and amortization	`DepreciationAndAmortization`	$741.06K	USD	1 Quarter
Depreciation and amortization	`DepreciationAndAmortization`	$1.48M	USD	3 Qtrs
Amortization of note premiums	`AmortizationOfDebtDiscountPremium`	$416.29K	USD	3 Qtrs
Amortization of note premiums	`AmortizationOfDebtDiscountPremium`	$945.11K	USD	3 Qtrs
Noncash gain in equity investment	`NonCashGainInEquityInvestment`	$87.20K	USD	3 Qtrs
Non-controlling interest	`NetIncomeLossAttributableToNoncontrollingInterest`	$-95.13K	USD	3 Qtrs
Non-controlling interest	`NetIncomeLossAttributableToNoncontrollingInterest`	$2.47K	USD	1 Quarter
Receivables	`IncreaseDecreaseInReceivables`	$-75.00K	USD	3 Qtrs
Other receivables	`IncreaseDecreaseInOtherReceivables`	$517.99K	USD	3 Qtrs
Other receivables	`IncreaseDecreaseInOtherReceivables`	$620.39K	USD	3 Qtrs
Other current assets	`IncreaseDecreaseInOtherCurrentAssets`	$2.90M	USD	3 Qtrs
Other current assets	`IncreaseDecreaseInOtherCurrentAssets`	$138.65K	USD	3 Qtrs
Accounts payable	`IncreaseDecreaseInAccountsPayable`	$2.33M	USD	3 Qtrs
Accounts payable	`IncreaseDecreaseInAccountsPayable`	$990.93K	USD	3 Qtrs
Accrued expenses	`IncreaseDecreaseInAccruedLiabilities`	$459.69K	USD	3 Qtrs
Accrued expenses	`IncreaseDecreaseInAccruedLiabilities`	$-2.16M	USD	3 Qtrs
Other	`IncreaseDecreaseInOtherOperatingLiabilities`	$31.64K	USD	3 Qtrs
Other	`IncreaseDecreaseInOtherOperatingLiabilities`	$-4.48K	USD	3 Qtrs
NET CASH USED IN OPERATING ACTIVITIES	`NetCashProvidedByUsedInOperatingActivitiesContinuingOperations`	$-24.50M	USD	3 Qtrs
NET CASH USED IN OPERATING ACTIVITIES	`NetCashProvidedByUsedInOperatingActivitiesContinuingOperations`	$-53.69M	USD	3 Qtrs
Cash paid for acquisitions	`PaymentsToAcquireAssetsInvestingActivities`	$10.00M	USD	3 Qtrs
Purchases of property and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$1.25M	USD	3 Qtrs
Purchases of property and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$1.14M	USD	3 Qtrs
Proceeds from sale of fixed assets	`ProceedsFromSaleOfPropertyPlantAndEquipment`	$500.00	USD	3 Qtrs
Purchase of marketable securities	`PaymentsToAcquireMarketableSecurities`	$46.37M	USD	3 Qtrs
Proceeds from sale of marketable securities	`ProceedsFromSaleAndMaturityOfMarketableSecurities`	$6.59M	USD	3 Qtrs
Proceeds from sale of marketable securities	`ProceedsFromSaleAndMaturityOfMarketableSecurities`	$19.41M	USD	3 Qtrs
NET CASH PROVIDED BY (USED IN) INVESTING ACTIVITIES	`NetCashProvidedByUsedInInvestingActivitiesContinuingOperations`	$-41.03M	USD	3 Qtrs
NET CASH PROVIDED BY (USED IN) INVESTING ACTIVITIES	`NetCashProvidedByUsedInInvestingActivitiesContinuingOperations`	$8.28M	USD	3 Qtrs
Principal payments on capital leases and notes payable	`RepaymentsOfLongTermCapitalLeaseObligations`	$160.16K	USD	3 Qtrs
Principal payments on capital leases and notes payable	`RepaymentsOfLongTermCapitalLeaseObligations`	$257.18K	USD	3 Qtrs
Proceeds from issuance of common stock and preferred stock, net	`ProceedsFromIssuanceOrSaleOfEquity`	$172.64M	USD	3 Qtrs
Proceeds from the exercise of warrants and stock options	`ProceedsFromExerciseOfWarrantsAndStockOptions`	$12.37M	USD	3 Qtrs
Proceeds from the exercise of warrants and stock options	`ProceedsFromExerciseOfWarrantsAndStockOptions`	$313.75K	USD	3 Qtrs
NET CASH PROVIDED BY FINANCING ACTIVITIES	`NetCashProvidedByUsedInFinancingActivitiesContinuingOperations`	$153.59K	USD	3 Qtrs
NET CASH PROVIDED BY FINANCING ACTIVITIES	`NetCashProvidedByUsedInFinancingActivitiesContinuingOperations`	$184.76M	USD	3 Qtrs
NET INCREASE (DECREASE) IN CASH	`CashAndCashEquivalentsPeriodIncreaseDecrease`	$119.24M	USD	3 Qtrs
NET INCREASE (DECREASE) IN CASH	`CashAndCashEquivalentsPeriodIncreaseDecrease`	$-45.26M	USD	3 Qtrs
CASH AT BEGINNING OF PERIOD	`CashAndCashEquivalentsAtCarryingValue`	$87.25M	USD	Point-in-time
CASH AT BEGINNING OF PERIOD	`CashAndCashEquivalentsAtCarryingValue`	$138.35M	USD	Point-in-time
CASH AT BEGINNING OF PERIOD	`CashAndCashEquivalentsAtCarryingValue`	$19.11M	USD	Point-in-time
CASH AT BEGINNING OF PERIOD	`CashAndCashEquivalentsAtCarryingValue`	$132.51M	USD	Point-in-time
CASH AT END OF PERIOD	`CashAndCashEquivalentsAtCarryingValue`	$87.25M	USD	Point-in-time
CASH AT END OF PERIOD	`CashAndCashEquivalentsAtCarryingValue`	$138.35M	USD	Point-in-time
CASH AT END OF PERIOD	`CashAndCashEquivalentsAtCarryingValue`	$19.11M	USD	Point-in-time
CASH AT END OF PERIOD	`CashAndCashEquivalentsAtCarryingValue`	$132.51M	USD	Point-in-time
Interest paid	`InterestPaid`	$21.48K	USD	3 Qtrs
Interest paid	`InterestPaid`	$11.15K	USD	3 Qtrs
Common stock issued to Novartis for asset acquisition	`CommonStockIssuedForAssetAcquisition`	$25.00M	USD	3 Qtrs

Stockholders Equity 26 line items

Line Item	Tag	Value	Unit	Period
Beginning Balance Amount	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$130.74M	USD	Point-in-time
Beginning Balance Amount	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$165.99M	USD	Point-in-time
Beginning Balance Amount	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$25.73M	USD	Point-in-time
Exercise of warrants, Amount	`StockIssuedDuringPeriodValueExerciseOfWarrants`	$10.15M	USD	Annual
Exercise of warrants, Amount	`StockIssuedDuringPeriodValueExerciseOfWarrants`	$270.62K	USD	3 Qtrs
Stock options exercised, Amount	`StockIssuedDuringPeriodValueStockOptionsExercised`	$2.73M	USD	Annual
Stock options exercised, Amount	`StockIssuedDuringPeriodValueStockOptionsExercised`	$43.13K	USD	3 Qtrs
Stock options exercised	`StockIssuedDuringPeriodSharesStockOptionsExercised`	454,863.00	shares	Annual
Stock options exercised	`StockIssuedDuringPeriodSharesStockOptionsExercised`	17,500.00	shares	3 Qtrs
Stock-based compensation	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$6.71M	USD	3 Qtrs
Stock-based compensation	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$5.70M	USD	Annual
Exercise of exchange rights, Amount	`ExchangeRightsExercisedDuringPeriodValue`	$3.07K	USD	3 Qtrs
Stock issuances, Shares	`StockIssuedDuringPeriodSharesNewIssues`	3.07M	shares	Point-in-time
Stock issuances, Shares	`StockIssuedDuringPeriodSharesNewIssues`	6.33M	shares	Point-in-time
Settlements related to derivative liability	`OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax`	$5.96M	USD	Annual
Deconsolidation of Calando Pharmaceuticals, Inc.	`NoncontrollingInterestDecreaseFromDeconsolidation`	$1.30M	USD	Annual
Foreign Currency Translation Adjustments	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$-65.95K	USD	3 Qtrs
Foreign Currency Translation Adjustments	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$-1.98K	USD	1 Quarter
Net loss	`ProfitLoss`	$-36.29M	USD	3 Qtrs
Net loss	`ProfitLoss`	$-11.63M	USD	1 Quarter
Net loss	`ProfitLoss`	$-67.20M	USD	3 Qtrs
Net loss	`ProfitLoss`	$-58.73M	USD	Annual
Net loss	`ProfitLoss`	$-15.94M	USD	1 Quarter
Ending Balance Amount	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$130.74M	USD	Point-in-time
Ending Balance Amount	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$165.99M	USD	Point-in-time
Ending Balance Amount	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$25.73M	USD	Point-in-time

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.